Ampio Pharmaceuticals Inc Stock News

U.S. drug developer Ampio Pharmaceuticals Inc said on Friday it would begin an early stage study of its experimental treatment, Ampion, in COVID-19 patients after it received regulatory clearance from

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company"), is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As par

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d

10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M

Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema

10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M

Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program

If you're interested in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), then you might want to consider its beta (a...

The

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscr